Skip to Content
Merck
All Photos(1)

Key Documents

M7920

Sigma-Aldrich

Minoxidil Sulfate

Synonym(s):

U-58838

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C9H15N5O4S
CAS Number:
Molecular Weight:
289.31
MDL number:
UNSPSC Code:
12352107
PubChem Substance ID:
NACRES:
NA.77

form

powder

Quality Level

originator

Johnson & Johnson

storage temp.

−20°C

SMILES string

Nc1cc(nc(N)[n+]1OS([O-])(=O)=O)N2CCCCC2

InChI

1S/C9H15N5O4S/c10-7-6-8(13-4-2-1-3-5-13)12-9(11)14(7)18-19(15,16)17/h6H,1-5H2,(H4,10,11,12,15,16,17)

InChI key

OEOLOEUAGSPDLT-UHFFFAOYSA-N

Looking for similar products? Visit Product Comparison Guide

Application

Minoxidil sulfate (MXS) has been used as a drug agent to study its effects on alopecia in corticotropin-releasing factor over-expressing (CRF-OE) mice. It has also been used as a positive control in an assay for the culturing of rat vibrissa follicles.

Biochem/physiol Actions

Minoxidil sulfate (MXS) is an endogenous derivative of minoxidil. It possesses greater aqueous solubility and is a potent vasodilator. MXS has the potential to treat androgenic alopecia or male baldness.

Features and Benefits

This compound was developed by Johnson & Johnson. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Other Notes

Active metabolite of minoxidil.

Pictograms

Exclamation mark

Signal Word

Warning

Hazard Statements

Hazard Classifications

Acute Tox. 4 Oral - Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

Target Organs

Respiratory system

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

K S Atwal
Journal of cardiovascular pharmacology, 24 Suppl 4, S12-S17 (1994-01-01)
KATP openers are recognized as having a therapeutic potential for the treatment of various cardiovascular and noncardiovascular diseases. However, the first-generation agents open KATP in a variety of tissues that limit their potential clinical utility. This review describes our studies
K Bray et al.
Naunyn-Schmiedeberg's archives of pharmacology, 345(2), 244-250 (1992-02-01)
The effects of the K+ channel blockers tedisamil and glibenclamide on cromakalim- and minoxidil sulphate-induced 42K+ and 86Rb+ efflux and vasorelaxation in rat aorta, were investigated. In aortic strips preloaded with 42K+ or 86Rb+, cromakalim (1 mumol/l) induced increases in
K M Bray et al.
The Journal of biological chemistry, 267(17), 11689-11692 (1992-06-15)
The K+ channel openers, including cromakalim, pinacidil, minoxidil sulfate, diazoxide, and nicorandil, form a chemically heterogeneous group of compounds, which relax smooth muscle by opening plasmalemmal K+ channels. At present it is not known whether these drugs elicit their effects
Nagendra S Ningaraj et al.
Cancer research, 63(24), 8899-8911 (2003-12-26)
Brain tumor microvessels/capillaries limit drug delivery to tumors by forming a blood-brain tumor barrier (BTB). The BTB overexpresses ATP-sensitive potassium (K(ATP)) channels that are barely detectable in normal brain capillaries, and which were targeted for BTB permeability modulation. In a
Pharmacological effects of drug conjugates: is morphine 6-glucuronide an exception?
G J Mulder
Trends in pharmacological sciences, 13(8), 302-304 (1992-08-01)

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service